Alpine Immune Sciences (ALPN) Appoints Jorn Drappa to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Alpine Immune Sciences Appoints Jörn Drappa, MD, PhD, to Board of Directors
July 19, 2022 8:05 AM EDT- 20-year industry veteran with extensive global clinical development leadership experience in autoimmune and inflammatory diseases -
SEATTLE--(BUSINESS WIRE)-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced the appointment of Jörn Drappa, MD, PhD, to its Board of Directors.
We are very pleased to welcome Dr. Drappa to our Board of Directors. Jörn brings a tremendous depth of experience leading the successful development of immunology drugs across both... More
